1. Suchak R, Murray LJ. Generic portfolio management: a paradigm for minimizing risk and maximizing value. Journal of Generic Medicines. 2016;13:63
http://journals.sagepub.com/doi/abs/10.1177/1741134316677850
.
2. Financial Times
https://www.ft.com/content/6645b174-2371-11e8-ae48-60d3531b7d11
3. US FDA
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm591184.htm
4. Barei F, Le Pen C, Simoens S. The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation. Generics and Biosimilars Initiative Journal (GaBI Journal). 2013;2(1):13–9.
5. Center for Drug Evaluation and Research (CDER). Guidance for industry: applications covered by section 505(b)(2). 1999.
http://www.fda.gov/downloads/Drugs/Guidances/ucm079345.pdf
.